EverSource Wealth Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

EverSource Wealth Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$491	Sell	91 -56,891	-100%	-$261K	﹤0.01%	4071
2025 Q4	$203K	Sell	56,982 -93,899	-62%	-$298K	0.01%	937
2025 Q3	$438K	Buy	150,881 +56,954	+61%	+$194K	0.02%	548
2025 Q2	$338K	Buy	93,927 +93,811	+80,872%	+$280K	0.02%	616
2025 Q1	$347	Buy	+116	New	+$362	﹤0.01%	3571
2024 Q4	–	Sell	-69	Closed	-$231	–	3753
2024 Q3	$231	Sell	69 -49	-42%	-$178	﹤0.01%	2947
2024 Q2	$451	Buy	+118	New	+$440	﹤0.01%	2918

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EverSource Wealth Advisors's AVIR Position: Q1 2026 in Review

EverSource Wealth Advisors reduced its Atea Pharmaceuticals (AVIR) stake by 100% in Q1 2026, selling an estimated $261K and leaving 91 shares worth $491. The position accounts for ﹤0.01% of the portfolio, ranked #4071.

EverSource Wealth Advisors first reported a position in AVIR in Q2 2024 and has held it in 7 quarters since. The position peaked at $438K in Q3 2025. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

EverSource Wealth Advisors held 91 shares of Atea Pharmaceuticals worth $491 as of Q1 2026.
EverSource Wealth Advisors sold 56,891 Atea Pharmaceuticals shares in Q1 2026, an estimated $261K.
Atea Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #4071 holding.
EverSource Wealth Advisors first reported a position in Atea Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
EverSource Wealth Advisors's Atea Pharmaceuticals position peaked at $438K in Q3 2025.
127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.